Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report

Rasim Somer Diler, Aysegul Yolga, Ayse Avci
Department of Child and Adolescent Psychiatry, Cukurova University, Faculty of Medicine, Adana, Turkey

Introduction

As in adults, selective serotonin reuptake inhibitors (SSRIs) have been increasingly used in the treatment of children and adolescents [1, 2]. Because of this wide use even low-frequency adverse effects are becoming more prevalent [3], and reports of extrapyramidal symptoms (e.g. dystonia, dyskinesia, akathisia, parkinsonism and neuroleptic malignant syndrome) associated with SSRI use have been accumulating in the literature [3, 4]. Epidemiological studies suggest that EPS occur in about 1 per 1000 adult patients treated with SSRIs [5, 6].

Case report

“A” was a 15-year-old female in whom a major depressive disorder, OCD (washing, cleaning and checking) and CD according to DSM-IV were diagnosed at age 14 [8]. There was no family neuropsychiatric history and initial medical work-up including whole blood count, blood chemistry panel, liver function tests, ECG, thyroid function tests and child neurology consult revealed no significance. Fluoxetine 20 mg PO qd was started and then increased to 40 mg in six weeks due to slow response to the treatment. We also used 25–50 mg/day quatiapine (an atypical serotonin-dopamine receptor antagonist) between 2½ and 8½ months of fluoxetine treatment when OCD symptoms markedly diminished and CD symptoms were improved. After three more months of 20 mg/day fluoxetine monotherapy (after 12½ months of fluoxetine introduction) A developed “cogwheel rigidity”, “bradykinesia”, and “episodic torticollis lasting 5–10 minutes three to four times a day”. A was seen with torticollis, which looked similar to that seen in patients on typical antipsychotics. The physical and neurological examination was normal except for “cogwheel rigidity and Bradykinesia”. No physical findings or abnormal movements were observed in A. Benztropine 2 mg IV resulted in rapid relief of...
torticollis. Whole blood count, blood chemistry panel, liver function tests, ECG and creatine phosphokinase level were normal.

Given the effectiveness of fluoxetine treatment, A and A’s parents were unwilling to stop fluoxetine, and benzotropine 1 mg PO tid was prescribed along with fluoxetine. A received no EPS for 10 days and benztropine was gradually withdrawn over a week. She re-experienced mild bradykinesia and cogwheel rigidity, but no torticollis, one day after cessation of benztropine. Benzotropine 1 mg PO tid was restarted and EPS were resolved within two days. Benztropine and fluoxetine were used for a further 2 months. A has not experienced EPS since cessation of medication 2 months ago.

Discussion

Given the absence of a drug-related cause for EPS (quatiapine poses a relatively low risk for EPS and our patient had not taken quatiapine for three months) [4] and the rapid and time-related response to benztropine, we conclude that A experienced parkinsonian symptoms (bradykinesia and cogwheel rigidity) and an acute dystonic reaction (episodic torticollis) related to fluoxetine. This case report adds to the accumulating literature and is evidence that EPS can and do occur in young patients on SSRI.

The majority of SSRI-related reactions occurred within the first month of treatment, but they have also been reported to occur within a number of months [4]. Our case was a female adolescent on a long-term moderate fluoxetine dose without rapid dose adjustment. The literature offers no supporting evidence for a consistent risk factor, although total daily dose of SSRI, rapid dose escalations, increased age, female gender, concurrent psychotropics known to precipitate EPS, and concurrent disease states such as Parkinson’s disease are cited [3–6].

As in our report, fluoxetine is the biggest offender in the literature on adults and acute dystonia is the most frequent EPS finding [3, 4, 9]. EPS is usually reversible and conveniently managed by discontinuing the responsible agent, lowering its dose or using drugs similar to those employed in neuroleptic-induced EPS [9]. On the other hand, co-prescribing of SSRIs and neuroleptics may increase neuroleptic plasma levels (due to P-450.2D6 system blockage), increasing the likelihood of EPS [10, 11].

Conclusions

Clinicians should be aware of the SSRIs as a potential causative factor for EPS. Greater awareness of this potential role could lead to more frequent recognition and help to decrease morbidity. The emergence of SSRI-induced EPS in children and adolescents should be the subject of further research in large clinical samples.

References

5 Choo V. Paroxetine and extrapyramidal reactions. Lancet 1993;341:624.
The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:
EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch